Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19451179 
Liu F, et al. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-32 19451179
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S199-p - Tau iso8 (human)
Orthologous residues
Tau (human): S516‑p, Tau iso2 (human): S141‑p, Tau iso3 (human): S105‑p, Tau iso5 (human): S199‑p, Tau iso6 (human): S141‑p, Tau iso7 (human): S170‑p, Tau iso8 (human): S199‑p, Tau (mouse): S491‑p, Tau iso3 (mouse): S188‑p, Tau iso7 (mouse): S148‑p, Tau (rat): S510‑p, Tau (cow): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S202-p - Tau iso8 (human)
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

T205-p - Tau iso8 (human)
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease
siRNA increase OGT shRNA
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

T212-p - Tau iso8 (human)
Orthologous residues
Tau (human): T529‑p, Tau iso2 (human): T154‑p, Tau iso3 (human): T118‑p, Tau iso5 (human): T212‑p, Tau iso6 (human): T154‑p, Tau iso7 (human): T183‑p, Tau iso8 (human): T212‑p, Tau (mouse): T504‑p, Tau iso3 (mouse): T201‑p, Tau iso7 (mouse): T161‑p, Tau (rat): T523‑p, Tau (cow): T219‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
OGT (human) decrease
siRNA increase OGT shRNA
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S214-p - Tau iso8 (human)
Orthologous residues
Tau (human): S531‑p, Tau iso2 (human): S156‑p, Tau iso3 (human): S120‑p, Tau iso5 (human): S214‑p, Tau iso6 (human): S156‑p, Tau iso7 (human): S185‑p, Tau iso8 (human): S214‑p, Tau (mouse): S506‑p, Tau iso3 (mouse): S203‑p, Tau iso7 (mouse): S163‑p, Tau (rat): S525‑p, Tau (cow): S221‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human

T217-p - Tau iso8 (human)
Orthologous residues
Tau (human): T534‑p, Tau iso2 (human): T159‑p, Tau iso3 (human): T123‑p, Tau iso5 (human): T217‑p, Tau iso6 (human): T159‑p, Tau iso7 (human): T188‑p, Tau iso8 (human): T217‑p, Tau (mouse): T509‑p, Tau iso3 (mouse): T206‑p, Tau iso7 (mouse): T166‑p, Tau (rat): T528‑p, Tau (cow): T224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S262-p - Tau iso8 (human)
Orthologous residues
Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S396-p - Tau iso8 (human)
Orthologous residues
Tau (human): S713‑p, Tau iso2 (human): S307‑p, Tau iso3 (human): S271‑p, Tau iso5 (human): S365‑p, Tau iso6 (human): S338‑p, Tau iso7 (human): S367‑p, Tau iso8 (human): S396‑p, Tau (mouse): S688‑p, Tau iso3 (mouse): S385‑p, Tau iso7 (mouse): S345‑p, Tau (rat): S707‑p, Tau (cow): S403‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S404-p - Tau iso8 (human)
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S422-p - Tau iso8 (human)
Orthologous residues
Tau (human): S739‑p, Tau iso2 (human): S333‑p, Tau iso3 (human): S297‑p, Tau iso5 (human): S391‑p, Tau iso6 (human): S364‑p, Tau iso7 (human): S393‑p, Tau iso8 (human): S422‑p, Tau (mouse): S714‑p, Tau iso3 (mouse): S411‑p, Tau iso7 (mouse): S371‑p, Tau (rat): S733‑p, Tau (cow): S429‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  Alzheimer's disease
 Relevant cell lines - cell types - tissues:  'brain, cerebellum'
 Cellular systems studied:  tissue
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  O-GlcNAc glycosylation
 Comments:  hyperphosphorylation of this site decreases O-GlcNAcylation of tau
Associated Diseases
Diseases: Alterations: Comments:
Alzheimer's disease increased

S510-p - Tau (rat)
Orthologous residues
Tau (human): S516‑p, Tau iso2 (human): S141‑p, Tau iso3 (human): S105‑p, Tau iso5 (human): S199‑p, Tau iso6 (human): S141‑p, Tau iso7 (human): S170‑p, Tau iso8 (human): S199‑p, Tau (mouse): S491‑p, Tau iso3 (mouse): S188‑p, Tau iso7 (mouse): S148‑p, Tau (rat): S510‑p, Tau (cow): S206‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
okadaic acid no change compared to control
fasting increase

S513-p - Tau (rat)
Orthologous residues
Tau (human): S519‑p, Tau iso2 (human): S144‑p, Tau iso3 (human): S108‑p, Tau iso5 (human): S202‑p, Tau iso6 (human): S144‑p, Tau iso7 (human): S173‑p, Tau iso8 (human): S202‑p, Tau (mouse): S494‑p, Tau iso3 (mouse): S191‑p, Tau iso7 (mouse): S151‑p, Tau (rat): S513‑p, Tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON no change compared to control
okadaic acid no change compared to control
fasting no change compared to control

T516-p - Tau (rat)
Orthologous residues
Tau (human): T522‑p, Tau iso2 (human): T147‑p, Tau iso3 (human): T111‑p, Tau iso5 (human): T205‑p, Tau iso6 (human): T147‑p, Tau iso7 (human): T176‑p, Tau iso8 (human): T205‑p, Tau (mouse): T497‑p, Tau iso3 (mouse): T194‑p, Tau iso7 (mouse): T154‑p, Tau (rat): T516‑p, Tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
fasting increase
okadaic acid increase

T523-p - Tau (rat)
Orthologous residues
Tau (human): T529‑p, Tau iso2 (human): T154‑p, Tau iso3 (human): T118‑p, Tau iso5 (human): T212‑p, Tau iso6 (human): T154‑p, Tau iso7 (human): T183‑p, Tau iso8 (human): T212‑p, Tau (mouse): T504‑p, Tau iso3 (mouse): T201‑p, Tau iso7 (mouse): T161‑p, Tau (rat): T523‑p, Tau (cow): T219‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
fasting increase
okadaic acid increase

S525-p - Tau (rat)
Orthologous residues
Tau (human): S531‑p, Tau iso2 (human): S156‑p, Tau iso3 (human): S120‑p, Tau iso5 (human): S214‑p, Tau iso6 (human): S156‑p, Tau iso7 (human): S185‑p, Tau iso8 (human): S214‑p, Tau (mouse): S506‑p, Tau iso3 (mouse): S203‑p, Tau iso7 (mouse): S163‑p, Tau (rat): S525‑p, Tau (cow): S221‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON decrease
fasting decrease
okadaic acid increase

T528-p - Tau (rat)
Orthologous residues
Tau (human): T534‑p, Tau iso2 (human): T159‑p, Tau iso3 (human): T123‑p, Tau iso5 (human): T217‑p, Tau iso6 (human): T159‑p, Tau iso7 (human): T188‑p, Tau iso8 (human): T217‑p, Tau (mouse): T509‑p, Tau iso3 (mouse): T206‑p, Tau iso7 (mouse): T166‑p, Tau (rat): T528‑p, Tau (cow): T224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
fasting increase
okadaic acid increase

S573-p - Tau (rat)
Orthologous residues
Tau (human): S579‑p, Tau iso2 (human): S204‑p, Tau iso3 (human): S168‑p, Tau iso5 (human): S262‑p, Tau iso6 (human): S204‑p, Tau iso7 (human): S233‑p, Tau iso8 (human): S262‑p, Tau (mouse): S554‑p, Tau iso3 (mouse): S251‑p, Tau iso7 (mouse): S211‑p, Tau (rat): S573‑p, Tau (cow): S269‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
okadaic acid increase

S707-p - Tau (rat)
Orthologous residues
Tau (human): S713‑p, Tau iso2 (human): S307‑p, Tau iso3 (human): S271‑p, Tau iso5 (human): S365‑p, Tau iso6 (human): S338‑p, Tau iso7 (human): S367‑p, Tau iso8 (human): S396‑p, Tau (mouse): S688‑p, Tau iso3 (mouse): S385‑p, Tau iso7 (mouse): S345‑p, Tau (rat): S707‑p, Tau (cow): S403‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON increase
fasting increase
okadaic acid increase

S715-p - Tau (rat)
Orthologous residues
Tau (human): S721‑p, Tau iso2 (human): S315‑p, Tau iso3 (human): S279‑p, Tau iso5 (human): S373‑p, Tau iso6 (human): S346‑p, Tau iso7 (human): S375‑p, Tau iso8 (human): S404‑p, Tau (mouse): S696‑p, Tau iso3 (mouse): S393‑p, Tau iso7 (mouse): S353‑p, Tau (rat): S715‑p, Tau (cow): S411‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DON no change compared to control
fasting no change compared to control
okadaic acid increase

S733-p - Tau (rat)
Orthologous residues
Tau (human): S739‑p, Tau iso2 (human): S333‑p, Tau iso3 (human): S297‑p, Tau iso5 (human): S391‑p, Tau iso6 (human): S364‑p, Tau iso7 (human): S393‑p, Tau iso8 (human): S422‑p, Tau (mouse): S714‑p, Tau iso3 (mouse): S411‑p, Tau iso7 (mouse): S371‑p, Tau (rat): S733‑p, Tau (cow): S429‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  brain
 Cellular systems studied:  tissue
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
okadaic acid increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.